Barrett ADT - Search Results

1

Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.

Vannice KS, Wilder-Smith A, Barrett ADT, Carrijo K, Cavaleri M, de Silva A, Durbin AP, Endy T, Harris E, Innis BL, Katzelnick LC, Smith PG, Sun W, Thomas SJ, Hombach J. Vannice KS, et al. Among authors: barrett adt. Vaccine. 2018 Jun 7;36(24):3411-3417. doi: 10.1016/j.vaccine.2018.02.062. Epub 2018 Mar 7. Vaccine. 2018. PMID: 29525283 Free PMC article.

2

Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.

Beasley DW, Li L, Suderman MT, Guirakhoo F, Trent DW, Monath TP, Shope RE, Barrett AD. Beasley DW, et al. Vaccine. 2004 Sep 9;22(27-28):3722-6. doi: 10.1016/j.vaccine.2004.03.027. Vaccine. 2004. PMID: 15315852

3

Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil.

Engel AR, Vasconcelos PF, McArthur MA, Barrett AD. Engel AR, et al. Vaccine. 2006 Apr 5;24(15):2803-9. doi: 10.1016/j.vaccine.2006.01.009. Epub 2006 Jan 18. Vaccine. 2006. PMID: 16464518

4

17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005.

Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE. Barrett AD, et al. Vaccine. 2007 Apr 12;25(15):2758-65. doi: 10.1016/j.vaccine.2006.12.015. Epub 2006 Dec 28. Vaccine. 2007. PMID: 17368349

5

Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.

Hombach J, Cardosa MJ, Sabchareon A, Vaughn DW, Barrett AD. Hombach J, et al. Vaccine. 2007 May 22;25(21):4130-9. doi: 10.1016/j.vaccine.2007.02.079. Epub 2007 Mar 16. Vaccine. 2007. PMID: 17428588

6

Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses.

Roehrig JT, Hombach J, Barrett AD. Roehrig JT, et al. Viral Immunol. 2008 Jun;21(2):123-32. doi: 10.1089/vim.2008.0007. Viral Immunol. 2008. PMID: 18476771 Review.

7

Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development.

Thomas SJ, Hombach J, Barrett A. Thomas SJ, et al. Vaccine. 2009 Jan 14;27(3):355-68. doi: 10.1016/j.vaccine.2008.10.086. Epub 2008 Nov 18. Vaccine. 2009. PMID: 19022321 Review.

8

Genetic characterization of early isolates of Japanese encephalitis virus: genotype II has been circulating since at least 1951.

Schuh AJ, Li L, Tesh RB, Innis BL, Barrett AD. Schuh AJ, et al. J Gen Virol. 2010 Jan;91(Pt 1):95-102. doi: 10.1099/vir.0.013631-0. Epub 2009 Sep 23. J Gen Virol. 2010. PMID: 19776238 Free PMC article.

9

Development pathway for biodefense vaccines.

Barrett AD, Beasley DW. Barrett AD, et al. Vaccine. 2009 Nov 5;27 Suppl 4:D2-7. doi: 10.1016/j.vaccine.2009.07.094. Vaccine. 2009. PMID: 19837280 Review.

10

Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus.

Whiteman MC, Li L, Wicker JA, Kinney RM, Huang C, Beasley DW, Chung KM, Diamond MS, Solomon T, Barrett AD. Whiteman MC, et al. Vaccine. 2010 Jan 22;28(4):1075-83. doi: 10.1016/j.vaccine.2009.10.112. Epub 2009 Nov 5. Vaccine. 2010. PMID: 19896447

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

224 results

Search Page